Synhumans for Peptech
19 March, 2007 by Staff WritersPeptech has released a new antibody technology platform called Synhumanisation.
Schering-Plough to buy Organon BioSciences
13 March, 2007 by Staff WritersContrary to recent moves by Big Pharma to shed workers and costs, Schering-Plough is buying up.
Border security for fruit flies
08 March, 2007 by Joanne FinlayUnderstanding molecular signatures of fruit flies could avert disaster for primary producers.
The ugly face of Ug99
01 March, 2007 by Joanne FinlayAustralian wheat growers have been warned that one of the world's most devastating diseases of wheat, stem rust, is back.
Antibody collaboration for EvoGenix and Vegenics
28 February, 2007 by Kate McDonaldAustralian biotech companies EvoGenix and Vegenics have entered into a technology collaboration agreement to target vascular endothelial growth factor D (VEGF-D), a mediator in angiogenesis.
Oral delivery of TNF blockers
22 February, 2007 by Kate McDonaldTNF blocker a second major application for Apollo Life Sciences' Oradel platform, currently in development for oral insulin.
Roche divides and sets out to conquer
07 February, 2007 by Kate McDonaldPharma giant Roche announces plans to restructure R&D activities and increase staff and spending.
Getting big for BIO
06 February, 2007 by Kate McDonaldLook out for the March/April issue of Australian Life Scientist, featuring our big preview of BIO2007 along with new developments in RNAi and proteomics.
Luck of the draw for salty genes
06 February, 2007 by Kate McDonaldA lucky coincidence has led Australian plant researchers to two new genes responsible for salt tolerance in wheat.
Freeze-dried bunny killer
02 February, 2007 by Staff WritersNSW scientists are researching how to develop a freeze-dried form of the rabbit Calicivirus to improve its effectiveness.
Apollo gets ready for lift-off
02 February, 2007 by Kate McDonaldSuccessful toxicology trials means Apollo Life Science can move towards human clinical trials for its insulin in tablet form.
Phylogica's pipeline expansion
01 February, 2007 by Kate McDonaldWest Australian biotech Phylogica has appointed former Pharmaxis scientist Dr Doug Francis to head its drug development team.
Canada completes human metabolome first draft
30 January, 2007 by Staff WritersCanadian researchers have completed the first draft of the human metabolome.
Blood pressure drug reverses muscle wasting in mice
30 January, 2007 by Staff WritersA drug commonly used to lower blood pressure can prevent muscle degeneration and even reverse muscle wasting in genetically engineered mice.
Clinuvel moves to phase III for PLE
25 January, 2007 by Kate McDonaldClinuvel receives regulatory approval for clinical trials for its photo-protective drug CUV1647.
